Urogen Pharma (NASDAQ:URGN) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Urogen Pharma (NASDAQ:URGN) have been assigned an average rating of “Moderate Buy” from the eight analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $33.2857.

A number of analysts have weighed in on URGN shares. Oppenheimer reiterated an “outperform” rating on shares of Urogen Pharma in a research report on Monday, March 2nd. D. Boral Capital reissued a “buy” rating and set a $33.00 price objective on shares of Urogen Pharma in a report on Monday, March 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday, January 21st.

Insider Activity

In other Urogen Pharma news, General Counsel Jason Drew Smith sold 7,479 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total value of $147,261.51. Following the transaction, the general counsel directly owned 51,326 shares in the company, valued at $1,010,608.94. The trade was a 12.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mark Schoenberg sold 7,373 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total transaction of $145,174.37. Following the completion of the transaction, the insider owned 144,985 shares in the company, valued at approximately $2,854,754.65. This trade represents a 4.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 4.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of URGN. Paradigm Biocapital Advisors LP acquired a new stake in Urogen Pharma during the 3rd quarter valued at $84,111,000. Soleus Capital Management L.P. bought a new position in Urogen Pharma in the 2nd quarter valued at $29,934,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Urogen Pharma in the fourth quarter worth $26,350,000. MPM Bioimpact LLC boosted its stake in Urogen Pharma by 597.3% in the fourth quarter. MPM Bioimpact LLC now owns 941,378 shares of the company’s stock worth $22,047,000 after purchasing an additional 806,378 shares in the last quarter. Finally, TCG Crossover Management LLC bought a new stake in shares of Urogen Pharma during the third quarter worth $14,311,000. 91.29% of the stock is owned by institutional investors and hedge funds.

Urogen Pharma Trading Down 1.0%

NASDAQ URGN opened at $17.00 on Thursday. Urogen Pharma has a 1-year low of $3.42 and a 1-year high of $30.00. The company has a market capitalization of $827.56 million, a price-to-earnings ratio of -5.31 and a beta of 1.34. The stock’s 50 day moving average is $19.84 and its two-hundred day moving average is $20.75.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Monday, March 2nd. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.12. The company had revenue of $37.84 million during the quarter, compared to analyst estimates of $39.92 million. On average, analysts predict that Urogen Pharma will post -3.12 earnings per share for the current year.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.